LongBio Pharma Posts Stable Share Base in First HKEX Monthly Return Post-IPO

Bulletin Express07-06

LongBio Pharma (Suzhou) Co., Ltd. (LONGBIO-B) filed its inaugural Monthly Return with Hong Kong Exchanges and Clearing Limited for the period ended 30 June 2026, covering activity from its Main Board debut on 5 June to month-end.

Authorised and registered share capital remained unchanged at 74.19 million ordinary shares with a par value of RMB 1 each, comprising 72.93 million H shares listed in Hong Kong and 1.26 million unlisted domestic shares.

No movements occurred in June: issued H shares and unlisted shares were flat at 72.93 million and 1.26 million respectively, with zero treasury shares reported. Consequently, total issued shares stayed at 74.19 million.

Management confirmed that the public float exceeded the Initial Prescribed Threshold of 21.05 percent of issued H shares, satisfying Main Board Rule 13.32B.

The company reported no outstanding share options, warrants, convertible securities or other equity-linked instruments during the period, and affirmed full compliance with all applicable listing and regulatory requirements as of 30 June 2026.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1196851211?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-06 19:07","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1196851211","market":"hk","top_or_hot":-1,"title":"LongBio Pharma Posts Stable Share Base in First HKEX Monthly Return Post-IPO","media":"Bulletin Express","content":"<p>LongBio Pharma (Suzhou) Co., Ltd. (LONGBIO-B) filed its inaugural Monthly Return with Hong Kong Exchanges and Clearing Limited for the period ended 30 June 2026, covering activity from its Main Board debut on 5 June to month-end.</p>\n<p>Authorised and registered share capital remained unchanged at 74.19 million ordinary shares with a par value of RMB 1 each, comprising 72.93 million H shares listed in Hong Kong and 1.26 million unlisted domestic shares.</p>\n<p>No movements occurred in June: issued H shares and unlisted shares were flat at 72.93 million and 1.26 million respectively, with zero treasury shares reported. Consequently, total issued shares stayed at 74.19 million.</p>\n<p>Management confirmed that the public float exceeded the Initial Prescribed Threshold of 21.05 percent of issued H shares, satisfying Main Board Rule 13.32B.</p>\n<p>The company reported no outstanding share options, warrants, convertible securities or other equity-linked instruments during the period, and affirmed full compliance with all applicable listing and regulatory requirements as of 30 June 2026.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>LongBio Pharma Posts Stable Share Base in First HKEX Monthly Return Post-IPO</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nLongBio Pharma Posts Stable Share Base in First HKEX Monthly Return Post-IPO\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-07-06 19:07</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>LongBio Pharma (Suzhou) Co., Ltd. (LONGBIO-B) filed its inaugural Monthly Return with Hong Kong Exchanges and Clearing Limited for the period ended 30 June 2026, covering activity from its Main Board debut on 5 June to month-end.</p>\n<p>Authorised and registered share capital remained unchanged at 74.19 million ordinary shares with a par value of RMB 1 each, comprising 72.93 million H shares listed in Hong Kong and 1.26 million unlisted domestic shares.</p>\n<p>No movements occurred in June: issued H shares and unlisted shares were flat at 72.93 million and 1.26 million respectively, with zero treasury shares reported. Consequently, total issued shares stayed at 74.19 million.</p>\n<p>Management confirmed that the public float exceeded the Initial Prescribed Threshold of 21.05 percent of issued H shares, satisfying Main Board Rule 13.32B.</p>\n<p>The company reported no outstanding share options, warrants, convertible securities or other equity-linked instruments during the period, and affirmed full compliance with all applicable listing and regulatory requirements as of 30 June 2026.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"01779","symbol_name":"天辰生物-B","start_time":0,"source_url":"","article_id":"1196851211","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1196851211","pubTimestamp":1783336036,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"LongBio Pharma (Suzhou) Co., Ltd. (LONGBIO-B) filed its inaugural Monthly Return with Hong Kong Exchanges and Clearing Limited for the period ended 30 June 2026, covering activity from its Main Board...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"01779":"天辰生物-B"},"translate_title":"龙生物制药首次公开募股后首份港交所月度报告显示稳定的股份基础","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01779":1},"content_text":"LongBio Pharma (Suzhou) Co., Ltd. (LONGBIO-B) filed its inaugural Monthly Return with Hong Kong Exchanges and Clearing Limited for the period ended 30 June 2026, covering activity from its Main Board debut on 5 June to month-end.\nAuthorised and registered share capital remained unchanged at 74.19 million ordinary shares with a par value of RMB 1 each, comprising 72.93 million H shares listed in Hong Kong and 1.26 million unlisted domestic shares.\nNo movements occurred in June: issued H shares and unlisted shares were flat at 72.93 million and 1.26 million respectively, with zero treasury shares reported. Consequently, total issued shares stayed at 74.19 million.\nManagement confirmed that the public float exceeded the Initial Prescribed Threshold of 21.05 percent of issued H shares, satisfying Main Board Rule 13.32B.\nThe company reported no outstanding share options, warrants, convertible securities or other equity-linked instruments during the period, and affirmed full compliance with all applicable listing and regulatory requirements as of 30 June 2026.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"0","news_tag":"SGX","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.46.0","shortVersion":"4.46.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1196851211","isCrawlerRequest":true}